(19)
(11) EP 2 641 601 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.09.2016 Bulletin 2016/38

(45) Mention of the grant of the patent:
06.07.2016 Bulletin 2016/27

(21) Application number: 13168383.1

(22) Date of filing: 07.08.2007
(51) International Patent Classification (IPC): 
A61K 31/573(2006.01)
A61K 31/69(2006.01)
A61P 35/00(2006.01)
 A61K 31/454(2006.01)
A61K 39/395(2006.01)
A61K 45/06(2006.01)

(54)

Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib

Verfahren zur Behandlung von Multiplem-Myelomen mit hilfe von Kombinationstherapien auf Basis von HuLuc63 und Bortezomib

Procédés de traitement du myélome multiple à l'aide de polythérapies à base de HuLuc63 et bortezomib

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
HR

(30) Priority: 07.08.2006 US 836185 P
15.06.2007 US 944262 P

(43) Date of publication of application:
25.09.2013 Bulletin 2013/39

(62) Application number of the earlier application in accordance with Art. 76 EPC:
07840746.7 / 2068874

(73) Proprietors:
  • AbbVie Biotherapeutics Inc.
    Redwood City, CA 94063 (US)
  • Dana-Farber Cancer Institute, Inc.
    Boston, MA 02215 (US)

(72) Inventors:
  • Afar, Daniel
    Fremont, California 94555 (US)
  • Andersen, Kenneth C.
    Wellesley, Massachusetts 02482 (US)
  • Tai, Yu-Tzu
    Newton, Massachusetts 02459 (US)

(74) Representative: Roques, Sarah Elizabeth et al
J A Kemp 14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
US-A1- 2005 025 763
 US-A1- 2006 024 296
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).